Navigation Links
Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
Date:10/26/2009

SCHAUMBURG, Ill., Oct. 26 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company with a focus on injectable products, today announced that Jeffery M. Yordon, chief executive officer, founder and chairman of the board of Sagent Pharmaceuticals, has accepted invitations to present at upcoming conferences sponsored by Oppenheimer & Co. Inc. and Lazard Capital Markets LLC.

On Tuesday, November 3, 2009, Mr. Yordon will present at the Oppenheimer 20th Annual Healthcare Conference at 11:25am Eastern Time. This conference, which is taking place November 3-4 at the Waldorf=Astoria Hotel in New York, NY, will feature presentations by leading public and private companies in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries.

Two weeks following, Mr. Yordon will present at the Lazard Capital Markets 6th Annual Healthcare Conference at 10:55am Eastern Time on Tuesday, November 17, 2009. This conference, which is being held November 17-18 at the St. Regis Hotel in New York, NY, will feature presentations from 150 leading healthcare companies, five expert panel discussions, a "Conference Top Picks" panel with Lazard Capital Markets research analysts, and Senator Tom Daschle as the keynote speaker, on "Solving the Healthcare Crisis."

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.

SOURCE Sagent Pharmaceuticals, Inc.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
2. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
3. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
5. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
6. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
7. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
8. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
9. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)... -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ), the ... and manufacturing data that support SB-525, its gene therapy program ... of the American Society of Hematology (ASH) being held in ... 2016. "We have developed an improved gene therapy ... highly competitive, and we remain on track to file an ...
(Date:12/5/2016)... Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., a ... data from two Phase I trials evaluating its ... 58th annual meeting of the American Society of ... . The two datasets show encouraging efficacy ... leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... 2016 , ... "FCPX Overlay Glare is a tool that utilizes light found ... or complicated compositing," said Christina Austin - CEO of Pixel Film Studios. , ... lights that simulates the look of a glare. Just drag and drop to ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... been featured in SuperbCrew magazine, a leading online tech news platform connecting technology ... now featured on SuperbCrew.com, explores the state of enterprise mobility security today, and ...
(Date:12/5/2016)... ... , ... “Epilepsy Awareness,” which can be found at the ... about epilepsy, bearing down on the social stigma and lack of public education ... within their lifetime. With such a large percentage of people affected, it’s critically ...
(Date:12/5/2016)... ... December 05, 2016 , ... Eating disorders are equal ... Castlewood Treatment Centers has always been to promote the power of recovery, and ... possible. In that spirit, Castlewood has announced two new hires, both Outreach Directors ...
(Date:12/5/2016)... Shrewsbury, PA (PRWEB) , ... December 05, 2016 , ... ... of necessity for the betterment of both the smaller rider and the horse. Smaller ... performance. The Saddle Sidekick is designed to fit over a properly fitted western saddle ...
Breaking Medicine News(10 mins):